Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2001

View Archived Issues

Cyclic D,L-alpha peptides exert antibacterial activity against MRSA

Cataracts improve with N-acetylcarnosine drops

Lifestyle modification or Glucophage markedly reduce progression to type 2 diabetes

LAR formulations of Amylin's synthetic exendin-4 offer potential for monthly dosing

BioCryst's oral influenza neuraminidase inhibitor to enter phase III trial in U.S.

Onyx regains development rights for nonintravenous administration of ONYX-015

Encouraging phase I results reported for Supratek's lead oncology product

Geron and Kyowa Hakko select telomerase inhibitor for development

Five statins available in the U.S. as alternatives to Baycol

Schering-Plough and Roche resolve peginterferon patent disputes

Phase I trial initiated for Inspire's sinusitis therapy

Phase I study successful for Prescient NeuroPharma's anhydrovinblastine

Flavonoid consumption associated with reduced incidence of COPD

SI-6601D found useful for local therapy in rheumatoid arthritis patients

Roche designs new compounds for the treatment of type 2 diabetes

Compounds for the treatment of cellular protein transport disorders reported by Procter & Gamble

Icos patents new potent and selective PDE4 inhibitors

Merck & Co. describes novel derivatives as selective ligands for GABA-A receptors

C&C Research presents several new series of compounds with antiestrogenic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...